



an Open Access Journal by MDPI

Recent Advances in Amyloid Research: Molecular Biology, Pharmacology, Pathophysiology, Diagnostic Technology, and Therapeutics

Guest Editors:

Prof. Dr. Masahide Yazaki

Department of Neuro Health Innovation, Institute for Biomedical Sciences, Shinshu University, Matsumoto 390-8621, Japan

Prof. Yoshiki Sekijima

Department of Neurology and Rheumatology, Shinshu University School of Medicine, Matsumoto, Japan

Deadline for manuscript submissions:

closed (15 January 2019)

Message from the Guest Editors

Dear Colleagues,

Amyloidosis is one of the representative misfolded protein disorders, resulting from intra or extracellular accumulation of amyloid fibrils. While amyloidosis was previously quite an intractable disease, recent basic research on the pathogenesis of several amyloidoses has gradually been able to elucidated several types of amyloidosis, which have become treatable. However, we need more detailed information on amyloidosis and its pathogenesis. Therefore, this Special Issue of *Biomedicines* will focus on recent advance in amyloid research, including new insights into molecular biology, pharmacology, pathophysiology, and therapeutics. In addition, as it will be more important to make a correct diagnosis in the early stages of the disease after the establishment of effective treatments, submissions regarding new diagnostic procedures are welcome.



mdpi.com/si/16507

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)